GBM6-AD / University of Minnesota - LARVOL DELTA

Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Jennie Taylor | Active, not recruiting ➔ Completed

Trial completion • Anaplastic Astrocytoma • Anaplastic Oligoastrocytoma • Astrocytoma • Brain Cancer • CNS Tumor • Glioma • Malignant Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD8 • CXCL10

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: OX2 Therapeutics

New P1 trial • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Jennie Taylor | Trial completion date: Aug 2023 ➔ Aug 2024

Trial completion date • Anaplastic Astrocytoma • Anaplastic Oligoastrocytoma • Astrocytoma • Brain Cancer • CNS Tumor • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD4 • CD8 • CXCL10

Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Jennie Taylor | Trial primary completion date: Feb 2023 ➔ Aug 2022

Trial primary completion date • Anaplastic Astrocytoma • Anaplastic Oligoastrocytoma • Astrocytoma • Brain Cancer • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD4 • CD8 • CXCL10